A new drug for male pattern baldness has shown breakthrough results in large clinical trials

One of the most impressive scientific breakthroughs in recent decades has been recorded in the treatment of androgenetic alopecia (male pattern baldness). A new topical medication, tested in two large phase III trials (Scalp 1 and Scalp 2) involving 1,465 patients, demonstrated an increase in hair count of up to 539% compared to placebo in the first study and 168% in the second. According to experts, such results have not been achieved in roughly 30 years.

The drug works locally at the level of hair follicles and blocks the influence of the hormone DHT (dihydrotestosterone), which is considered one of the key causes of male hair loss. Unlike traditional systemic treatments, the new product does not interfere with the body’s overall hormonal balance, which, according to the studies, keeps the side-effect profile at placebo levels.

Dermatologists call the results “historic” for patients with androgenetic alopecia and speak of a “new paradigm” in therapy. The developer company plans to complete safety data collection by spring 2026, after which it will submit parallel approval applications to regulatory authorities in the USA (FDA) and the EU (EMA). If approved, this will be the first new medication for male pattern baldness in 30 years.